ICYMI, this week we had stories on DAXI's BLA resubmission approval, sexual dysfunction and atopic dermatitis, and more.
New York becomes 25th state to grant nurse practitioners full practice authority.
As innovation in dermatology continues, so do questions on the efficacy of cannabinoid use for psoriasis, among other skin diseases.
A multicenter investigation provides information on the prevalence and incidence of alopecia areata in children.
A recent study showed that men with psoriasis have larger EAT-V than those without the skin disease.
This week's edition of the Mainstream Patients features stories about the causes of eczema, botox for TMJ, and more.
New government rule aims to address some of the cost disparity.
In this video interview, Darren Smith, MD, comments on the Renuvion/J-Plasma device (Apyx Medical) receiving an FDA warning for dermal resurfacing or skin contraction. He dives into how the device may be causing these issues, how this affects patients, and more.
Jonathan Silverberg, MD, the associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, joins us to discuss a poster from the December 2021 RAD conference.
Lawmakers want to expand telehealth options for children, cognitive research.
Unlike other psychological comorbidities, sexual dysfunction is a little explored field within AD.
In this week’s Pointers with Dr Portela, the 208SkinDoc lists the top 5 ingredients to look for when patients are choosing over the counter solutions.
Pandemic greatly accelerated consolidation, threatening the independent practice of medicine.
The Society of Dermatology Nurse Practitioners is having its annual conference this weekend, starting April 22 through 23 with a certification review course happening April 24 to 25, in Nashville, Tennessee.
Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.
Scientists from Mount Sinai have reported that a mutation of the ARID2 gene may be a key factor in the risk of melanoma turning metastatic.
A comprehensive review explored new uses of this popular technology in aesthetic and medical dermatology.
Chinese patients with moderate to severe crow’s feet lines reported high levels of satisfaction with onabotulinumtoxinA treatment, according to a recently published study.
Study compiles data, finds multiple specialties affected.
Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.